Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study

Table 3 Predicted and observed time to HCV RNA negativity

Patient	Predicted time (weeks) to HCV RNA negativity⁽¹⁾ with 10 MU/daily	Predicted time (weeks) to HCV RNA negativity⁽¹⁾ with 3 MU/daily	First observedHCV RNA negativity⁽¹⁾ (weeks)
1-A	11		12 ⁽²⁾
1-B	2		2
1-C	1.5		2
1-D	12		4–8
1-E	2.5		2
1-F	3.5		4
1-G	10.5		4–8
1-H	1		1
1-I	9		Positive at 24 weeks ⁽³⁾⁽⁴⁾
Group 1: HCV neg before 12 weeks	9 / 9 patients		8 / 9 patients
2-A	9	16	Positive at 24 weeks ⁽³⁾
2-B	1	1	1
2-C	1	2	1.5
2-D	Never	Never	Positive at 24 weeks ⁽³⁾
2-E	11	13	4–8
2-F	1	1.5	1.5
2-G	5.5	7	4–8
2-H	3	10	12–16
2-I	11	18	Positive at 24 weeks ⁽³⁾
2-J	3	5	4
2-K	7.5	24	Positive at 24 weeks ⁽³⁾
2-L	1.5	1.5	1.5
2-M	23	30	8–12
2-N	4	16	Positive at 24 weeks ⁽³⁾
2-O	Never	Never	Positive at 24 weeks ⁽³⁾
Group 2: HCV neg before 12 weeks	12 / 15 patients	7 / 15 patients	8 / 15 patients

Detection level for HCV RNA negativity is at < 500 copies/ml. 2) Patient 1-D had a viral breakthrough after 12 weeks and was HCV RNA positive at 24 weeks of treatment. 3) Patients with positive HCV RNA at 24 weeks stopped treatment according to protocol. 4) Patient 1-I was non-compliant from 8 weeks on according to self-report

ISSN: 1471-230X